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band structures, and misalignments of T-tubules with z-disk. We find that the
neuregulin-1-ErbB3 signaling and the baroreceptor reflex response, which
have been functionally associated, are both altered in the mutant mice. We fur-
ther demonstrate that ShcA interacts with Cav-1 and the costameric protein
plasma membrane Ca2+/calmodulin-dependent ATPase (PMCA), and that its
deletion leads to abnormal dystrophin signaling. Our studies demonstrate that
ShcA modulates ErbB3/Neuregulin and Cav-1/dystrophin signaling, two cru-
cial pathways for z-disk and costamere linkages in cardiomyocytes.
0213
Gevokizumab, an IL1-beta modulating antibody exerts promising
cardioprotective effects against ischemia-reperfusion injury in diabe-
tic rats.
Najah Harouki (1), Lionel Nicol (1), Nassiba Merabet (1), Jean-Paul
Henry (1), Pascale Gluais (2), Vincent Richard (1), Jérôme Roussel (2),
Christian Thuillez (1), Paul Mulder (1)
(1) Inserm U1096, Rouen, France – (2) Institut de recherche internation-
nal Servier, Suresnes, France
Aims: Enhanced myocardial interleukin-1 beta (IL1-β) production is
involved in ischemia/reperfusion (I/R) induced left ventricular (LV) dysfunc-
tion. We tested neutralization of IL-1β as a potential therapeutic target for the
treatment of I/R induced LV dysfunction.
Methods: We assessed in diabetic (Goto Kakizaki, GK) rats the preventive
effects of gevokizumab, a potent modulator of IL-1β, administered once a
week, started 4 weeks prior to a 20 min of transient ischemia induced by left
coronary artery occlusion and continued 90 days after I/R, on LV remodeling/
function (echocardiography) 7 and 90 days after I/R. LV hemodynamics (LV
catheterization), LV tissue perfusion (MRI) and LV collagen density (image
analysis) were assessed 90 days after I/R.
Results: I/R induced early LV expansion followed by late LV dilatation,
associated with LV dysfunction as well as after 90 days, reduced LV tissue per-
fusion and LV collagen accumulation. Gevokizumab limited both early LV
expansion as well as late LV dilatation, associated with an improved LV func-
tion. Ninety days after I/R, gevokizumab improved both LV systolic and LV dia-
stolic functions, illustrated by the increase in LV end-systolic pressure volume
relation, and the reductions in LV end-diastolic pressure and LV end-diastolic
pressure volume relation. Moreover, long-term gevokizumab moderately
increased LV tissue perfusion and significantly reduced LV collagen density.
Conclusions: Our results, obtained using a clinically relevant model of I/R,
suggest a therapeutic benefit of the IL-1β modulating antibody, gevokizumab, in
myocardial I/R injury.
LVDD: left ventricular diastolic diameters; LVFS:LV fractional short-
ening; LVESPVR and LVEDPVR: LV end-diastolic and end-systolic pressure
volume relations. *:p<0.05 vs GK; † p<0.05 vs GK I/R
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Aims: Cardiac interleukin-1 beta (IL1-β) production is enhanced acutely
after myocardial infarction and is involved in myocardial damages. We tested
if early and delayed IL1-β modulations by IL-1β antibody, gevokizumab, pre-
vent left ventricular (LV) remodeling and endothelial dysfunction induced by
LV ischemia/reperfusion (I/R) in diabetic rats.
Methods: Gevokizumab (Gevo; 10 mg/kg) was administered 1 hour
(early) or 7 days (delayed) following reperfusion, after a 20 min of transient
ischemia induced by LV artery occlusion and continued every week for
90 days. Delayed perindopril (1 mg/kg) was used as a positive control. LV
remodeling and function were assessed (Echocardiography) at 7 and 90 days.
LV hemodynamics (Millar catheterization) and relaxation of isolated coronary
arteries to acetylcholine (Mulvany wiregraph) were evaluated at 90 days.
Collagen density and leukocytes infiltration were evaluated (Histology) at
90 days.
Results: At 7 days, early Gevo limited the early LV expansion and reduc-
tion of FS induced by I/R. At 90 days both of early and delayed Gevo as well
as perindopril limited in a similar manner, the LV late dilatation, the reduction
of FS and LV systolic and diastolic dysfunction induced by I/R. At 90 days,
GK coronary endothelium-dependent relaxation to acetylcholine was impaired
by I/R (59±13 vs.17±4%, p<0.05). Early, delayed Gevo and perindopril
restored the (86±4, 92±2 and 98±1% respectively; p<0.05 vs GK+I/R) coro-
nary relaxation to acetylcholine. Early, delayed Gevo and perindopril signifi-
cantly reduced collagen density and leukocytes infiltration at 90 days.
Conclusions: In a clinically relevant model of acute myocardial infarction,
the IL-1β antibody gevokizumab started early or late after myocardial reper-
fusion exerts immediate and late cardiovascular protection.
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